-
Spatial and single-cell explorations uncover prognostic significance and immunological functions of mitochondrial calcium uniporter in breast cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-17 Chia-Jung Li, Yen-Dun Tony Tzeng, Jui-Hu Hsiao, Ling-Ming Tseng, Tzu-Sheng Hsu, Pei-Yi Chu
The mitochondrial calcium uniporter (MCU) is a transmembrane protein facilitating the entry of calcium ions into mitochondria from the cell cytosol. Maintaining calcium balance is crucial for enhancing cellular energy supply and regulating cell death. The interplay of calcium balance through MCU and the sodium-calcium exchanger is known, but its regulation in the breast cancer tumor microenvironment
-
A novel immunogenic cell death-related classification indicates the immune landscape and predicts clinical outcome and treatment response in acute myeloid leukemia Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-16 Fangmin Zhong, Shuyang He, Ni Guo, Luyi Shi, Linlin Zhang, Hua Jin, Guangyao Kong
Immunogenic cell death (ICD) is closely related to anti-tumor therapy and regulates the tumor microenvironment (TME). This study aims to explore the molecular characteristics of ICD in acute myeloid leukemia (AML) and to analyze the value of ICD-related biomarkers in TME indication, prognosis prediction, and treatment response evaluation in AML. Single-sample gene set enrichment analysis was used to
-
Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-16 Yunxing Shi, Kai Li, Yichuan Yuan, Chenwei Wang, Zhiwen Yang, Dinglan Zuo, Yi Niu, Jiliang Qiu, Binkui Li, Yunfei Yuan, Wei He
N6-methyladenosine (m6A) is important in regulating mRNA stability, splicing, and translation, and it also contributes to tumor development. However, there is still limited understanding of the comprehensive effects of m6A modification patterns on the tumor immune microenvironment, metabolism, and drug resistance in hepatocellular carcinoma (HCC). In this study, we utilized unsupervised clustering
-
Exosomes biogenesis was increased in metformin-treated human ovary cancer cells; possibly to mediate resistance Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-16 Reza Abbasi, Vahid Nejati, Jafar Rezaie
Exosomes derived from tumor cells contribute to the pathogenesis of cancers. Metformin, the most usually used drug for type 2 diabetes, has been frequently investigated for anticancer effects. Here, we examined whether metformin affects exosomes signaling in human ovary cancer cells in vitro. Human ovary cancer cells, including A2780 and Skov3 cells, were treated with metformin for either 24–48 h.
-
Pan-inhibition of the three H2S synthesizing enzymes restrains tumor progression and immunosuppression in breast cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-16 Alyaa Dawoud, Rana A. Youness, Heba Nafea, Tamer Manie, Carole Bourquin, Csaba Szabo, Reham M. Abdel-Kader, Mohamed Z. Gad
Hydrogen sulfide (H2S) is a significant endogenous mediator that has been implicated in the progression of various forms of cancer including breast cancer (BC). Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) are the three principal mammalian enzymes responsible for H2S production. Overexpression of CBS, CSE and 3MST was found to be associated
-
Significance of PSCA as a novel prognostic marker and therapeutic target for cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-16 Tina Nayerpour Dizaj, Abolfazl Doustmihan, Behnaz Sadeghzadeh Oskouei, Morteza Akbari, Mehdi Jaymand, MirAhmad Mazloomi, Rana Jahanban-Esfahlan
One of the contributing factors in the diagnosis and treatment of most cancers is the identification of their surface antigens. Cancer tissues or cells have their specific antigens. Some antigens that are present in many cancers elicit different functions. One of these antigens is the prostate stem cell antigen (PSCA) antigen, which was first identified in the prostate. PSCA is a cell surface protein
-
Micropeptides: potential treatment strategies for cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-15 He Zhou, Yan Wu, Ji Cai, Dan Zhang, Dongfeng Lan, Xiaofang Dai, Songpo Liu, Tao Song, Xianyao Wang, Qinghong Kong, Zhixu He, Jun Tan, Jidong Zhang
Some noncoding RNAs (ncRNAs) carry open reading frames (ORFs) that can be translated into micropeptides, although noncoding RNAs (ncRNAs) have been previously assumed to constitute a class of RNA transcripts without coding capacity. Furthermore, recent studies have revealed that ncRNA-derived micropeptides exhibit regulatory functions in the development of many tumours. Although some of these micropeptides
-
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-15 Tong Chen, Mingzhao Wang, Yanchao Chen, Yutao Liu
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the absence of tumor-specific target antigen, the existence of immunosuppressive tumor microenvironment, restricted
-
The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitntriors Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-10 Claire Muller, Victorine Lacroix-Malgras, Jérôme Kluza, William Laine, Yonca Güler, Frédéric Bost, Michel Boisbrun, Sabine Mazerbourg, Stéphane Flament
The metabolism of cancer cells generally differs from that of normal cells. Indeed, most cancer cells have a high rate of glycolysis, even at normal oxygen concentrations. These metabolic properties can potentially be exploited for therapeutic intervention. In this context, we have developed troglitazone derivatives to treat hormone-sensitive and triple-negative breast cancers, which currently lack
-
Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-09 Ya-Xin Zhao, Han Wang, Si-Wei Zhang, Wei-Xin Zhang, Yi-Zhou Jiang, Zhi-Ming Shao
Extensive exploration of the molecular subtypes of triple-negative breast cancer (TNBC) is critical for advancing precision medicine. Notably, the luminal androgen receptor (LAR) subtype has attracted attention for targeted treatment combining androgen receptor antagonists and CDK4/6 inhibitors. Unfortunately, this strategy has proven to be of limited efficacy, highlighting the need for further optimization
-
Identification of fatty acids synthesis and metabolism-related gene signature and prediction of prognostic model in hepatocellular carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-07 Ai Zhengdong, Xing Xiaoying, Fu Shuhui, Liang Rui, Tang Zehui, Song Guanbin, Yang Li, Tang Xi, Liu Wanqian
Fatty acids synthesis and metabolism (FASM)-driven lipid mobilization is essential for energy production during nutrient shortages. However, the molecular characteristics, physiological function and clinical prognosis value of FASM-associated gene signatures in hepatocellular carcinoma (HCC) remain elusive. The Gene Expression Omnibus database (GEO), the Cancer Genome Atlas (TCGA), and International
-
MiR-380 inhibits the proliferation and invasion of cholangiocarcinoma cells by silencing LIS1 Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-06 Zhicheng Wei, Bowen Xu, Yanjiang Yin, Jianping Chang, Zhiyu Li, Yefan Zhang, Xu Che, Xinyu Bi
The objective of this study was to determine the role and regulatory mechanism of miR-380 in cholangiocarcinoma. The TargetScan database and a dual-luciferase reporter assay system were used to determine if LIS1 was a target gene of miR-380. The Cell Counting Kit 8 assay, flow cytometry, and Transwell assay were used to detect the effects of miR-380 and LIS1 on the proliferation, S-phase ratio, and
-
Retraction Note: TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-05 Jing Pei, Jing Zhang, Xiaowei Yang, Zhengsheng Wu, Chenyun Sun, Zhaorui Wang, Benzhong Wang
Retraction Note to: Cancer Cell Int (2019) 19:75 https://doi.org/10.1186/s12935-019-0791-4 The Editors-in-Chief retracted this article because of concerns regarding a number of figures presented in this work. These concerns call into question the article’s overall scientific soundness. An investigation conducted after its publication discovered similarities between images in this work: The panel labelled
-
Comprehensive analyses of the cancer-associated fibroblast subtypes and their score system for prediction of outcomes and immunosuppressive microenvironment in prostate cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-05 Ze Gao, Ning Zhang, Bingzheng An, Dawei Li, Zhiqing Fang, Dawei Xu
Cancer-associated fibroblasts (CAFs) drive cancer progression and treatment failure on one hand, while their tumor-restraining functions are also observed on the other. Recent single cell RNA sequencing (scRNA-seq) analyses demonstrates heterogeneity of CAFs and defines molecular subtypes of CAFs, which help explain their different functions. However, it remains unclear whether these CAF subtypes have
-
Correction to: N6‑methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-05 Chunying Zhang, Jiadi Chen, Jingyi Ren, Xiaoyu Li, Yaqin Zhang, Bihan Huang, Yihan Xu, Luyan Dong, Yingping Cao
Correction to: Cancer Cell International (2024) 24:96 https://doi.org/10.1186/s12935-024-03289-2 In this article [1], the order of the corresponding author appeared in the author list was incorrect. Prof. Yingping Cao should be listed as the last author. Chunying Zhang and Jiadi Chen were equally contributed to this work. Thus, they should be listed as the co first authors. The original article has
-
Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75 Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-03 Tingting Cai, Tao Feng, Guangren Li, Jin Wang, Shengming Jin, Dingwei Ye, Yiping Zhu
Bladder cancer (BCa) stands out as a prevalent and highly lethal malignancy worldwide. Chemoresistance significantly contributes to cancer recurrence and progression. Traditional Tumor Node Metastasis (TNM) stage and molecular subtypes often fail to promptly identify treatment preferences based on sensitivity. In this study, we developed a prognostic signature for BCa with uni-Cox + LASSO + multi-Cox
-
CCDC25 suppresses clear cell renal cell carcinoma progression by LATS1/YAP-mediated regulation of the hippo pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-03 Hongpei Tan, Jiahao Liu, Yanan Li, Ze Mi, Baiying Liu, Pengfei Rong
Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent renal cancers, and the molecular mechanisms underlying its progression are still not fully understood. The expression of CCDC25, a notably underexpressed gene in many tumors, has been understudied in ccRCC. This research aims to explore the role of CCDC25 in ccRCC's clinical outcomes and uncover the molecular pathways influenced by
-
Immune cell infiltration and drug response in glioblastoma multiforme: insights from oxidative stress-related genes Cancer Cell Int. (IF 5.8) Pub Date : 2024-04-02 Kan Wang, Yifei Xiao, Ruipeng Zheng, Yu Cheng
GBM, also known as glioblastoma multiforme, is the most prevalent and lethal type of brain cancer. The cell proliferation, invasion, angiogenesis, and treatment of gliomas are significantly influenced by oxidative stress. Nevertheless, the connection between ORGs and GBM remains poorly comprehended. The objective of this research is to investigate the predictive significance of ORGs in GBM and their
-
Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-30 Bing Liao, Jialing Wang, Yalin Yuan, Hongliang Luo, Xi Ouyang
Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range
-
β-hydroxybutyrate inhibits malignant phenotypes of prostate cancer cells through β-hydroxybutyrylation of indoleacetamide-N-methyltransferase Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-30 Yifan Zhang, Yunlong Li
Prostate cancer (PCa) is one of the most prevalent cancers in men and is associated with high mortality and disability rates. β-hydroxybutyrate (BHB), a ketone body, has received increasing attention for its role in cancer. However, its role in PCa remains unclear. This study aimed to explore the mechanism and feasibility of BHB as a treatment alternative for PCa. Colony formation assay, flow cytometry
-
The molecular subtyping and precision medicine in triple-negative breast cancer---based on Fudan TNBC classification Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-30 Lijuan Weng, Jianliang Zhou, Shenchao Guo, Nong Xu, Ruishuang Ma
Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and
-
The molecular characteristics could supplement the staging system of pT2/T3N0M0 esophageal squamous cell carcinoma: a translational study based on a cohort with over 20 years of follow-up Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-30 Wen-Mei Jiang, Jia-Yuan Tian, Yi-Han Guo, Li-Hong Qiu, Xing-Yu Luo, Yang-Yu Huang, Hao Long, Lan-Jun Zhang, Peng Lin, Xin-Xin Xu, Lei-Lei Wu, Guo-Wei Ma
This study aimed to construct a model based on 23 enrolled molecules to evaluate prognoses of pT2/3N0M0 esophageal squamous cell carcinoma (ESCC) patients with up to 20 years of follow-up. The lasso-Cox model was used to identify the candidate molecule. A nomogram was conducted to develop the survival model (molecular score, MS) based on the molecular features. Cox regression and Kaplan-Meier analysis
-
RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-29 Yue Yu, Zhihua Xu, Hao Zhou, Ruyan Xu, Jia Xu, Wenjun Liu, Yuxin Wu, Yue Qiu, Guangbo Zhang, Xue Huang, Yan Chen
Increasing evidence proves that RBP7 plays a significant role in breast cancer (BC). The present study was aimed to investigate the mechanism of RBP7. Western Blotting and qRT-PCR were performed for evaluating the expression levels. CCK8, colony forming, xenograft mouse model, wound healing and transwell assays were conducted to examine cell ability of proliferation, invasion and migration. Nile red
-
Low TYROBP expression predicts poor prognosis in multiple myeloma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-28 Hong Luo, Chengyun Pan, Li Wang, Lin Zheng, Shuyun Cao, Xiuying Hu, Tianzhen Hu, Naiqin Zhao, Qin Shang, Jishi Wang
Multiple myeloma (MM) is the second most common refractory hematologic cancer. Searching for new targets and prognostic markers for MM is significant. GSE39754, GSE6477 and GSE24080 were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) in MM versus healthy people from GSE39754 and GSE6477 were screened using limma package, and MM-related module genes
-
Characterization of the biological and transcriptomic landscapes of bone marrow-derived mesenchymal stem cells in patients with multiple myeloma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-27 Yu Lu, Chaohui Zheng, Wenxia Zhang, Xuan Liu, Ziwei Zhou, Zhenzhen Wang, Huan Hua, Zhengrong Song, Xuejun Zhang, Shuyi Liu, Leisheng Zhang, Fuxu Wang
Mesenchymal stem/stromal cells (MSCs) have been acknowledged as the most important stromal cells in the bone marrow (BM) microenvironment for physiologic hematopoiesis and the concomitant hematologic malignancies. However, the systematic and detailed dissection of the biological and transcriptomic signatures of BM-MSCs in multiple myeloma (MM) are largely unknown. In this study, we isolated and identified
-
The upregulation of VGF enhances the progression of oral squamous carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Chung-Hsien Chou, Chun-Han Yen, Chung-Ji Liu, Hsi-Feng Tu, Shu-Chun Lin, Kuo-Wei Chang
Oral squamous cell carcinoma (OSCC) is a prevalent neoplasm worldwide, necessitating a deeper understanding of its pathogenesis. VGF nerve growth factor inducible (VGF), a neuropeptide, plays critical roles in nerve and endocrine cell regulation. In this study, the TCGA datasets were initially screened, identifying the upregulation of VGF in various malignancies. We focused on OSCC cell lines, identifying
-
Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Qiang Yuan, Yunshu Shi, Yuhan Zhang, Yaqian Shi, Zubair Hussain, Jimin Zhao, Yanan jiang, Yan Qiao, Yaping Guo, Jing Lu, Ziming Dong, Zigang Dong, Junyong Wang, Kangdong Liu
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of digestive system tumor related death in the world. Unfortunately, effective chemopreventive agent is lack for patients with ESCC in clinical practice, which leads to the extremely high mortality rate. A library of prescribed drugs was screened for finding critical anti-tumor properties in ESCC cells. The phosphoproteomics, kinase
-
LncRNA RASAL2-AS1 promotes METTL14-mediated m6A methylation in the proliferation and progression of head and neck squamous cell carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Meiting Rong, Ming Zhang, Feihong Dong, Ke Wu, Bingkun Cai, Jinrui Niu, Le Yang, Zhongyan Li, Hui-yi Lu
Long non-coding RNAs (lncRNAs) are key regulators of the 6-methyladenosine (m6A) epigenetic modification, playing a role in the initiation and progression of tumors. However, the regulatory mechanisms in head and neck squamous cell carcinoma (HNSCC) remain elusive. In this study, we investigated the molecular regulatory mechanisms of the lncRNA RASAL2-AS1 in the occurrence and development of HNSCC
-
Integrated analysis of disulfidptosis-related immune genes signature to boost the efficacy of prognostic prediction in gastric cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Jie Li, Tian Yu, Juan Sun, Mingwei Ma, Zicheng Zheng, Yixuan He, Weiming Kang, Xin Ye
Gastric cancer (GC) remains a malignant tumor with high morbidity and mortality, accounting for approximately 1,080,000 diagnosed cases and 770,000 deaths worldwide annually. Disulfidptosis, characterized by the stress-induced abnormal accumulation of disulfide, is a recently identified form of programmed cell death. Substantial studies have demonstrated the significant influence of immune clearance
-
LncRNA WFDC21P interacts with SEC63 to promote gastric cancer malignant behaviors by regulating calcium homeostasis signaling pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Jinyao Dong, Yongqiang Lv, Debin Meng, Ruyi Shi, Feng Li, Rui Guo, Yi Wang, Jiansheng Guo, Yanyan Zhang
Gastric cancer is currently estimated to be the fifth leading common cancer in the world, and responsible for about one million new cases and an estimated 769,000 cancer-related deaths each year. WFDC21P is long non-coding RNA and has been reported to play critical roles in serval types of cancer. Our research aims to investigate the biological effects and molecular mechanism of WFDC21P in gastric
-
Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-25 Tao Cheng, Changli Zhou, Sicheng Bian, Kelsey Sobeck, Yahui Liu
Resistance to targeted therapies represents a significant hurdle to successfully treating hepatocellular carcinoma (HCC). While epigenetic abnormalities are critical determinants of HCC relapse and therapeutic resistance, the underlying mechanisms are poorly understood. We aimed to address whether and how dysregulated epigenetic regulators have regulatory and functional communications in establishing
-
Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-19 Li Jia, Wenwei Hu, Xu Yan, Jie Shao, Yuhong Guo, Aimin Zhang, Lianzi Yu, Yunli Zhou, Yueguo Li, Li Ren, Dong Dong
Noninvasive biomarkers for the assessment of response to chemotherapy in advanced breast cancer (BCa) are essential for optimized therapeutic decision-making. We evaluated the potential of soluble Periostin (POSTN) in circulation as a novel biomarker for chemotherapy efficacy monitoring. Two hundred and thirty-one patients with different stages of BCa were included. Of those patients, 58 patients with
-
Aptamers as an approach to targeted cancer therapy Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-16 Fatemeh Mahmoudian, Azin Ahmari, Shiva Shabani, Bahman Sadeghi, Shohreh Fahimirad, Fahimeh Fattahi
Conventional cancer treatments can cause serious side effects because they are not specific to cancer cells and can damage healthy cells. Aptamers often are single-stranded oligonucleotides arranged in a unique architecture, allowing them to bind specifically to target sites. This feature makes them an ideal choice for targeted therapeutics. They are typically produced through the systematic evolution
-
Neighboring macrophage-induced alteration in the phenotype of colorectal cancer cells in the tumor budding area Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-14 Ichiro Kawamura, Rintaro Ohe, Kazushi Suzuki, Takanobu Kabasawa, Takumi Kitaoka, Daiichiro Takahara, Michihisa Kono, Naoya Uchiyama, Hiroaki Musha, Mitsuru Futakuchi, Fuyuhiko Motoi
A higher number of tumor buds in the invasive front of colorectal cancer (CRC) specimens has been shown to contribute to a poor prognosis in CRC patients. Because macrophages (Mφs) have been demonstrated to alter the phenotype of cancer cells, we hypothesized that the phenotype of CRC cells in the tumor budding (TB) area might be changed by the interaction between CRC cells and Mφs. We assessed the
-
Uncovering the cellular and omics characteristics of natural killer cells in the bone marrow microenvironment of patients with acute myeloid leukemia Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-14 Leisheng Zhang, Yunyan Sun, Chun-e Xue, Shuling Wang, Xianghong Xu, Chengyun Zheng, Cunrong Chen, Dexiao Kong
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy and the most frequently acute leukemia of stem cell precursors and the myeloid derivatives in adult. Longitudinal studies have indicated the therapeutic landscape and drug resistance for patients with AML are still intractable, which largely attribute to the deficiency of detailed information upon the pathogenesis. In this
-
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-12 Shan Ge, Yuwei Zhao, Jun Liang, Zhongning He, Kai Li, Guanghui Zhang, Baojin Hua, Honggang Zheng, Qiujun Guo, Runzhi Qi, Zhan Shi
Immune microenvironment and immunotherapy have become the focus and frontier of tumor research, and the immune checkpoint inhibitors has provided novel strategies for tumor treatment. Malignant pleural effusion (MPE) is a common end-stage manifestation of lung cancer, malignant pleural mesothelioma and other thoracic malignancies, which is invasive and often accompanied by poor prognosis, affecting
-
Decoding contextual crosstalk: revealing distinct interactions between non-coding RNAs and unfolded protein response in breast cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-11 Negin Karamali, Arshia Daraei, Arman Rostamlou, Roya Mahdavi, Zahra Akbari Jonoush, Nooshin Ghadiri, Zahra Mahmoudi, Amirhossein Mardi, Moslem Javidan, Sepideh Sohrabi, Behzad Baradaran
Breast cancer is significantly influenced by endoplasmic reticulum (ER) stress, impacting both its initiation and progression. When cells experience an accumulation of misfolded or unfolded proteins, they activate the unfolded protein response (UPR) to restore cellular balance. In breast cancer, the UPR is frequently triggered due to challenging conditions within tumors. The UPR has a dual impact on
-
Influential upregulation of KCNE4: Propelling cancer associated fibroblasts-driven colorectal cancer progression Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-10 Zizhen Zhang, Shengde Liu, Zhenghang Wang, Shuo Wang, Lei Jiang, Xicheng Wang, Jian Li, Lin Shen
Colorectal cancer (CRC) is a malignancy of remarkable heterogeneity and heightened morbidity. Cancer associated fibroblasts (CAFs) are abundant in CRC tissues and are essential for CRC growth. Here, we aimed to develop a CAF-related classifier for predicting the prognosis of CRC and identify critical pro-tumorigenic genes in CAFs. The mRNA expression and clinical information of CRC samples were sourced
-
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-10 Arefeh Zabeti Touchaei, Sogand Vahidi
Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to eliminate tumors. Immune checkpoint inhibitors (ICIs) block negative regulatory signals that prevent T cells from attacking cancer cells. Two key ICIs target the PD-1/PD-L1 pathway, which includes programmed death-ligand 1 (PD-L1) and its receptor programmed death 1 (PD-1). Another ICI targets cytotoxic
-
Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-10 Wanxian Chen, Deyi Geng, Jiasheng Chen, Xiaosha Han, Qihu Xie, Genghong Guo, Xuefen Chen, Wancong Zhang, Shijie Tang, Xiaoping Zhong
Despite advances in therapeutic strategies, resistance to immunotherapy and the off-target effects of targeted therapy have significantly weakened the benefits for patients with melanoma. Alternative splicing plays a crucial role in transcriptional reprogramming during melanoma development. In particular, aberrant alternative splicing is involved in the efficacy of immunotherapy, targeted therapy,
-
Perspective view of allogeneic IgG tumor immunotherapy Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-09 Ying Liu, Yuanyi Huang, Hong-Wei Cui, YingYing Wang, ZhaoWu Ma, Ying Xiang, Hong-Yi Xin, Jun-Qing Liang, Hong-Wu Xin
Allogeneic tumors are eradicated by host immunity; however, it is unknown how it is initiated until the report in Nature by Yaron Carmi et al. in 2015. Currently, we know that allogeneic tumors are eradicated by allogeneic IgG via dendritic cells. AlloIgG combined with the dendritic cell stimuli tumor necrosis factor alpha and CD40L induced tumor eradication via the reported and our proposed potential
-
Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-08 Baohong Jiang, Sixuan Wu, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Lianjie Ouyang, Wenjie Feng, Yeru Tan, Yuehua Li
Breast cancer is a major global health concern, and there is a continuous search for novel biomarkers to predict its prognosis. The mitochondrial protein NDUFAF6, previously studied in liver cancer, is now being investigated for its role in breast cancer. This study aims to explore the expression and functional significance of NDUFAF6 in breast cancer using various databases and experimental models
-
Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-05 Rong-Xuan Ning, Cun-Yu Liu, Shi-Qi Wang, Wen-Kai Li, Xia Kong, Zhi-Wei He
Tumor organoids, especially patient-derived organoids (PDOs) exhibit marked similarities in histopathological morphology, genomic alterations, and specific marker expression profiles to those of primary tumour tissues. They are applied in various fields including drug screening, gene editing, and identification of oncogenes. However, CAR-T therapy in the treatment of solid tumours is still at an exploratory
-
Mitochondrial respiratory chain component NDUFA4: a promising therapeutic target for gastrointestinal cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-05 Quanling Zhou, Xiaohui Li, Honglian Zhou, Juanjuan Zhao, Hailong Zhao, Lijuan Li, Ya Zhou
Gastrointestinal cancer, one of the most common cancers, continues to be a major cause of mortality and morbidity globally. Accumulating evidence has shown that alterations in mitochondrial energy metabolism are involved in developing various clinical diseases. NADH dehydrogenase 1 alpha subcomplex 4 (NDUFA4), encoded by the NDUFA4 gene located on human chromosome 7p21.3, is a component of mitochondrial
-
N6-methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-05 Yingping Cao, Chunying Zhang, Jiadi Chen, Jingyi Ren, Xiaoyu Li, Yaqin Zhang, Bihan Huang, Yihan Xu, Luyan Dong
N6-methyladenosine (m6A) is dysregulated in various cancers, including colorectal cancer (CRC). Herein, we assess the diagnostic potential of peripheral blood (PB) m6A levels in CRC. We collected PB from healthy controls (HCs) and patients with CRC, analyzed PB RNA m6A levels and the expression of m6A-related demethylase genes FTO and ALKBH5, cocultured CRC cells with PB mononuclear cells (PBMCs),
-
Transmembrane protein 176B regulates amino acid metabolism through the PI3K-Akt-mTOR signaling pathway and promotes gastric cancer progression Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-04 Jing Li, ZiQing Fang, Emre Dal, Hao Zhang, KeXun Yu, MengDi Ma, MingLiang Wang, Ruochuan Sun, MingDian Lu, HuiZhen Wang, YongXiang Li
The present study aimed to investigate the expression level, biological function, and underlying mechanism of transmembrane protein 176B (TMEM176B) in gastric cancer (GC). TMEM176B expression was detected by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting (WB). The function of TMEM176B was determined by various in vitro assays including colony formation, 5-ethynyl-2ʹ-deoxyuridine
-
Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-02 Hadeel Kheraldine, Ishita Gupta, Farhan Sachal Cyprian, Semir Vranic, Halema F. Al-Farsi, Maysaloun Merhi, Said Dermime, Ala-Eddin Al Moustafa
Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, including breast cancer. Nevertheless, the outcome of the combination of these inhibitors on HER2-positive breast cancer is not explored yet. Herein, we investigated the impact of DA and PD-L1 inhibitor
-
RGS20 promotes non-small cell lung carcinoma proliferation via autophagy activation and inhibition of the PKA-Hippo signaling pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-02 Xiaoyan Ding, Xiaoxia Li, Yanxia Jiang, Yujun Li, Hong Li, Lipeng Shang, Guilin Feng, Huhu Zhang, Ziyuan Xu, Lina Yang, Bing Li, Robert Chunhua Zhao
Novel therapeutic targets are urgently needed for treating drug-resistant non-small cell lung cancer (NSCLC) and overcoming drug resistance to molecular-targeted therapies. Regulator of G protein signaling 20 (RGS20) is identified as an upregulated factor in many cancers, yet its specific role and the mechanism through which RGS20 functions in NSCLC remain unclear. Our study aimed to identify the role
-
A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-02 Hefei Ren, Chang Liu, Cheng Zhang, Hongkun Wu, Jiafeng Zhang, Zhenhua Wang, Lei Chen, Huiquan Wang, Chenghao Shao, Lin Zhou
Cholangiocarcinoma represents a malignant neoplasm originating from the hepatobiliary tree, with a subset of tumors developing inside the liver. Intrahepatic cholangiocarcinomas (ICC) commonly exhibit an asymptomatic presentation, rendering both diagnosis and treatment challenging. Cuproptosis, an emerging regulated cell death pathway induced by copper ions, has garnered attention recently. As cancer
-
The circRNA hsa-circ-0013561 regulates head and neck squamous cell carcinoma development via the miR-7-5p/PDK3 axis Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-01 Kaisai Tian, Liying Zheng, Tailei Yuan, Xiaoping Chen, Qun Chen, Xiaocheng Xue, Shuixian Huang, Weining He, Mingming Jin, Yi Zhang
Circular RNAs (circRNAs) belong to a class of covalently closed single stranded RNAs that have been implicated in cancer progression. Former investigations showed that hsa-circ-0013561 is abnormally expressed in head and neck squamous cell carcinoma (HNSCC). Nevertheless, the role of hsa-circ-0013561 during the progress of HNSCC still unclear. Present study applied FISH and qRT-PCR to examine hsa-circ-0013561
-
PPP2R1B abolishes colorectal cancer liver metastasis and sensitizes Oxaliplatin by inhibiting MAPK/ERK signaling pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-03-01 Wei Liu, Jingtong Tang, Wei Gao, Jian Sun, Gang Liu, Jianping Zhou
Patients with colorectal cancer (CRC) with liver metastasis or drug resistance have a poor prognosis. Previous research has demonstrated that PPP2R1B inactivation results in the development of CRC. However, the role of PPP2R1B in CRC metastasis and drug resistance is unclear. Venny 2.1 was used to determine the intersection between survival-related differentially expressed genes (DEGs) and liver metastasis-related
-
The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-28 Samar Sami Alkafaas, Mohamed I. Elsalahaty, Doha F. Ismail, Mustafa Ali Radwan, Sara Samy Elkafas, Samah A. Loutfy, Rami M. Elshazli, Narjes Baazaoui, Ahmed Ezzat Ahmed, Wael Hafez, Mohanad Diab, Mohamed Sakran, Mohamed T. El-Saadony, Khaled A. El-Tarabily, Hani K. Kamal, Mohamed Hessien
Cancer chemoresistance is a problematic dilemma that significantly restrains numerous cancer management protocols. It can promote cancer recurrence, spreading of cancer, and finally, mortality. Accordingly, enhancing the responsiveness of cancer cells towards chemotherapies could be a vital approach to overcoming cancer chemoresistance. Tumour cells express a high level of sphingosine kinase-1 (SphK1)
-
Dormancy of cutaneous melanoma Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-28 Kathrin Singvogel, Birgit Schittek
Many cancer-related deaths including melanoma result from metastases that develop months or years after the initial cancer therapy. Even the most effective drugs and immune therapies rarely eradicate all tumor cells. Instead, they strongly reduce cancer burden, permitting dormant cancer cells to persist in niches, where they establish a cellular homeostasis with their host without causing clinical
-
LASS2 suppresses metastasis in multiple cancers by regulating the ferroptosis signalling pathway through interaction with TFRC Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-28 Yunfei Huang, Jie Du, Dan Li, Wei He, Zhouheng Liu, Li Liu, Xiaoli Yang, Xiaoming Cheng, Rui Chen, Yan Yang
As a key enzyme in ceramide synthesis, longevity assurance homologue 2 (LASS2) has been indicated to act as a tumour suppressor in a variety of cancers. Ferroptosis is involved in a variety of tumour processes; however, the role of LASS2 in regulating ferroptosis has yet to be explored. This article explores the potential underlying mechanisms involved. Bioinformatics tools and immunohistochemical
-
ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-24 Kegong Chen, Chunqiao Hong, Weibo Kong, Guanghua Li, Zhuang Liu, Kechao Zhu, Chen Lu, Panpan Si, Pan Gao, Guangyao Ning, Renquan Zhang
The role of Acyl-CoA dehydrogenase long chain (ACADL) in different tumor types had different inhibiting or promoting effect. However, its role in non-small cell lung cancer (NSCLC) carcinogenicity is not clear. In this study, we utilized The Cancer Genome Atlas (TCGA) database to analyze ACADL expression in NSCLC and its correlation with overall survival. Furthermore, we investigated the function of
-
SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-24 Haiting Zhou, Jiahao Li, Yi He, Xiaohui Xia, Junxia Liu, Huihua Xiong
SLC25A17, a peroxisomal solute carrier, has been implicated in various physiological and pathological processes. However, its precise roles and underlying mechanisms in triple-negative breast cancer (TNBC) remain incompletely understood. The expression and survival data of breast cancer were derived from TCGA and GEO databases. A variety of in vitro assays were conducted, including proliferation, apoptosis
-
Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-24 Mengchen Lyu, Lifeng Luo, Ling Zhou, Xiangran Feng, Jin Yang, Ziwei Xu, Xianwen Sun, Zhiyao Bao, Xiaofei Wang, Beili Gao, Yi Xiang
The incidence of multiple primary cancers (MPC), especially involving primary lung cancer (PLC) and primary hematologic malignancies (PHM), is rising. This study aims to analyze clinicopathological features, gene abnormalities, and prognostic outcomes in individuals diagnosed with PLC-PHM MPC. A retrospective analysis included 89 patients diagnosed with PLC-PHM MPC at the Respiratory or Hematology
-
Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-24 Bei Zhang, Yan Chen, Xinqi Chen, Zhiyao Ren, Hong Xiang, Lipeng Mao, Guodong Zhu
Apatinib was the first anti-angiogenic agent approved for treatment of metastatic gastric cancer (GC). However, the emergence of resistance was inevitable. Thus investigating new and valuable off-target effect of apatinib directly against cancer cells is of great significance. Here, we identified extra spindle pole bodies-like 1 (ESPL1) was responsible for apatinib resistance in GC cells through CRISPR
-
Retraction Note: GPX8 is transcriptionally regulated by FOXC1 and promotes the growth of gastric cancer cells through activating the Wnt signaling pathway Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-22 Hong Chen, Lu Xu, Zhi-li Shan, Shu Chen, Hao Hu
Cancer Cell International (2020) 20:596 https://doi.org/10.1186/s12935-020-01692-z The Editors-in-Chief have retracted this article. Concerns were raised regarding a number of figures, specifically: Figure 5h appears to overlap with Figure 4f in an article by different authors that was simultaneously under consideration with another journal [1]. Multiple figures, including Figures 2e, 3f and 5h appear
-
Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylation Cancer Cell Int. (IF 5.8) Pub Date : 2024-02-22 Xiaomei Wan, Jianwei Wang, Fang Fang, Yixin Hu, Zimu Zhang, Yanfang Tao, Yongping Zhang, Juanjuan Yu, Yumeng Wu, Bi Zhou, Hongli Yin, Li Ma, Xiaolu Li, Ran Zhuo, Wei Cheng, Shuqi Zhang, Jian Pan, Jun Lu, Shaoyan Hu
Acute myeloid leukemia (AML) is a malignancy of the hematopoietic system, and childhood AML accounts for about 20% of pediatric leukemia. ANP32B, an important nuclear protein associated with proliferation, has been found to regulate hematopoiesis and CML leukemogenesis by inhibiting p53 activity. However, recent study suggests that ANP32B exerts a suppressive effect on B-cell acute lymphoblastic leukemia